Price Action Report: What Next for Cerus Corporation Stock After Today’s Huge Decline?

Price Action Report: What Next for Cerus Corporation Stock After Today's Huge Decline?

The stock of Cerus Corporation (NASDAQ:CERS) is a huge mover today! About 640,011 shares traded hands. Cerus Corporation (NASDAQ:CERS) has risen 14.66% since March 8, 2016 and is uptrending. It has outperformed by 5.35% the S&P500.
The move comes after 8 months negative chart setup for the $606.35M company. It was reported on Oct, 11 by Barchart.com. We have $5.25 PT which if reached, will make NASDAQ:CERS worth $48.51 million less.

Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on November, 3. They expect $-0.16 earnings per share, up 5.88% or $0.01 from last year’s $-0.17 per share. After $-0.18 actual earnings per share reported by Cerus Corporation for the previous quarter, Wall Street now forecasts -11.11% EPS growth.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Out of 2 analysts covering Cerus (NASDAQ:CERS), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Cerus has been the topic of 3 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of Cerus Corporation (NASDAQ:CERS) earned “Buy” rating by BTIG Research on Wednesday, August 19. The firm has “Buy” rating by Zacks given on Tuesday, August 11. As per Thursday, December 17, the company rating was downgraded by Wedbush.

According to Zacks Investment Research, “Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company’s initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.”

Insitutional Activity: The institutional sentiment decreased to 1.69 in Q2 2016. Its down 0.06, from 1.75 in 2016Q1. The ratio fall, as 10 funds sold all Cerus Corporation shares owned while 26 reduced positions. 8 funds bought stakes while 53 increased positions. They now own 66.39 million shares or 1.07% more from 65.69 million shares in 2016Q1.
Manufacturers Life Ins Co The last reported 0% of its portfolio in the stock. Cortina Asset Ltd Liability Co holds 0.32% of its portfolio in Cerus Corporation (NASDAQ:CERS) for 1.13 million shares. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. The Vermont-based Birchview Limited Partnership has invested 0.12% in Cerus Corporation (NASDAQ:CERS). The New York-based Bamco Ny has invested 0% in Cerus Corporation (NASDAQ:CERS). Wells Fargo And Com Mn reported 5.24 million shares or 0.01% of all its holdings. Peak6 Invests Lp has invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). Blackrock Invest Mngmt Ltd Liability Com holds 0% or 391,197 shares in its portfolio. Wasatch last reported 105,000 shares in the company. Spot Trading Limited Liability Co has 22,039 shares for 0% of their US portfolio. Estabrook has 6,000 shares for 0% of their US portfolio. Moreover, Kennedy Capital Mgmt has 0.03% invested in Cerus Corporation (NASDAQ:CERS) for 215,342 shares. Magee Thomson Investment Partners Ltd Liability Company accumulated 198 shares or 0% of the stock. Blackrock Institutional Trust Communication Na last reported 2.57M shares in the company. Deutsche National Bank Ag accumulated 1.76M shares or 0.01% of the stock.

Insider Transactions: Since August 22, 2016, the stock had 0 buys, and 1 sale for $116,612 net activity. 17,150 Cerus Corporation (NASDAQ:CERS) shares with value of $116,612 were sold by Green Kevin Dennis.

More recent Cerus Corporation (NASDAQ:CERS) news were published by: Fool.com which released: “Cerus Corporation is Surging Today. Here’s Why.” on June 20, 2016. Also Businesswire.com published the news titled: “Cerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on October 05, 2016. Businesswire.com‘s news article titled: “Cerus Corporation Reports Second Quarter 2016 Results” with publication date: August 04, 2016 was also an interesting one.

CERS Company Profile

Cerus Corporation, incorporated on July 31, 1996, is a biomedical products company. The Firm is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Firm operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment